SYF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Synchrony Financial (SYF) does not currently present a compelling buy opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators are neutral to bearish, options data reflects a bearish sentiment, and recent financial performance shows mixed results. While there are some positive catalysts, such as share buybacks and favorable analyst upgrades, these are outweighed by negative sentiment in the news and limited upside potential in the near term.
The MACD is negatively expanding (-0.0868), indicating bearish momentum. RSI is neutral at 25.521, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 70.902), with resistance at R1: 75.381. Overall, the technical indicators suggest a neutral to bearish trend.
Some analysts, such as Baird and Compass Point, have upgraded the stock to 'Outperform' or 'Buy,' citing improved risk/reward and reasonable valuations.
The company is retiring 7% of its shares annually, which could support long-term shareholder value.
Revenue increased by 5.87% YoY in Q4 2025, showing growth in top-line performance.
Jim Cramer expressed a lack of confidence in SYF, favoring Capital One (COF) instead.
Analysts suggest limited upside compared to other investment opportunities, particularly in AI stocks.
Net income dropped by -3.05% YoY in Q4 2025, indicating pressure on profitability.
Options data reflects bearish sentiment, with a high put-call ratio and elevated implied volatility.
In Q4 2025, revenue increased by 5.87% YoY to $5.39 billion, and EPS grew by 6.81% YoY to 2.04. However, net income declined by -3.05% YoY to $730 million, reflecting challenges in profitability. The quarter appears mixed, with growth in revenue and EPS but weaker net income.
Analyst sentiment is mixed. Baird and Compass Point upgraded the stock to 'Outperform' and 'Buy,' respectively, citing favorable risk/reward and reasonable valuations. However, several firms, including UBS, Truist, and JPMorgan, lowered price targets while maintaining neutral ratings. The average price target remains in the $82-$96 range, suggesting limited upside from the current price of $71.025.
